Are night sweats, sleep disturbance, brain fog, hot flashes, irritability, or mood swings making the menopause transition harder than expected? Perimenopause and menopause are natural biological phases, but the symptoms can be intense enough to affect work, relationships, sleep, and emotional steadiness.

Shatavari (Asparagus racemosus) is one of Ayurveda’s most valued herbs for women’s health. In the Ayurvedic Pharmacopoeia of India, Shatavari is defined as the dried tuberous root of Asparagus racemosus Willd. Its rasa is described as madhura and tikta; its guna as guru and snigdha; its virya as shita; and its vipaka as madhura. Its listed karmas include balya, rasayana, medhya, pittahara, vatahara, vrishya, and stanyakara. This classical profile makes Shatavari especially relevant when the menopause transition presents with dryness, heat, depletion, disturbed sleep, and nervous-system sensitivity.

The 120-Day Perimenopause Trial: Nearly 73% Total MRS Reduction

A 2025 randomized, double-blind, placebo-controlled trial evaluated a standardized Shatavari root extract known as CL22209 in early perimenopausal women aged 40–50 years. Seventy-five participants were assigned to 50 mg/day, 100 mg/day, or placebo for 120 days, with outcomes measured using the Menopause Rating Scale, hot-flash scoring, menstrual-symptom assessment, endocrine markers, follicle count, and safety parameters.

The 100 mg/day group showed the strongest overall improvement:

  • Total Menopause Rating Scale score decreased by 72.95%, compared with 22.86% in the placebo group.
  • The 50 mg/day dose decreased total MRS score by 51.42%, showing a dose-responsive pattern.
  • Somatic symptoms decreased by 70.46%, including symptoms such as hot flashes, sleep problems, joint discomfort, and heart discomfort.
  • Psychological symptoms decreased by 73.04%, including mood disturbance, irritability, anxiety, and physical or mental exhaustion.
  • Urogenital symptoms decreased by 53.73%.
  • Hot-flash burden decreased by 39.81% in the 100 mg/day group, while the placebo group worsened by 7.76%.

No serious adverse events were reported in this trial. The recorded adverse events were mild and transient, including bloating and nausea in isolated cases.

The Hormonal Data: Endocrine Modulation During Perimenopause

The same 120-day trial measured endocrine markers before and after treatment. At 100 mg/day, Shatavari was associated with changes in hormones that are closely watched during the menopause transition.

Marker Change at 100 mg/day Clinical Relevance
FSH Decreased by 61.04% FSH commonly rises during the menopause transition as ovarian feedback changes.
LH Decreased by 42.7% LH is part of the hypothalamic-pituitary-ovarian signaling pattern that shifts during perimenopause.
AMH Increased by 269.69% AMH was tracked as an ovarian-reserve-related marker in the trial population.
Estradiol Increased by 5.28% Estradiol was measured to observe estrogenic endocrine trends during treatment.

These findings are best understood as endocrine modulation in early perimenopause, not as a guarantee of restored fertility or a replacement for individualized medical evaluation. Menopausal symptoms can overlap with thyroid, cardiovascular, metabolic, and mental-health concerns, so persistent or severe symptoms deserve proper clinical assessment.

Other Recent Controlled Trials

Several recent randomized controlled trials have placed Shatavari in a clearer clinical context for peri- and post-menopausal women. While the extracts, doses, populations, and durations differ, the overall direction is consistent: Shatavari preparations were associated with improvements in menopause-related symptom scores, quality-of-life measures, stress-related measures, and tolerability outcomes in the studied groups.

A 2024 double-blind, multicenter, randomized, placebo-controlled trial used 250 mg Shatavari root extract twice daily for 60 days in women with menopausal symptoms. The trial reported improvement in menopause-related complaints including hot flashes, night sweats, insomnia, anxiety or nervousness, vaginal dryness, and loss of libido, along with improved quality-of-life scores and no significant adverse events.

A 2025 randomized, double-blind, placebo-controlled trial in perimenopausal women used 300 mg/day Shatavari root extract for 8 weeks. The active group showed improvements in Menopause Rating Scale domains, perceived stress, fatigue, vigor, hot flashes, and selected hormonal measures, with no clinically concerning liver or kidney safety findings reported.

A 2025 multicenter randomized trial in women aged 45–65 years compared Shatavari root extract, a Shatavari-Ashwagandha combination, and placebo over 8 weeks. Shatavari was associated with improvement in Menopause Rating Scale and perceived-stress scores, while the combination arm showed stronger MRS improvement in that trial design. Mild adverse events such as nausea, loose stools, dizziness, and headache were reported across groups.

A 24-week randomized, double-blind, placebo-controlled trial in postmenopausal women evaluated Shatavari, Ashwagandha, and a combined arm. Shatavari was tested at 250 mg and 500 mg doses, and the trial reported dose-dependent improvement in menopause-related quality-of-life scores, vascular measures, bone-turnover markers, and inflammatory or oxidative markers. Mild gastrointestinal disturbances occurred in a few participants receiving 500 mg Shatavari, and no discontinuations due to adverse events were reported.

Combining Shatavari With Ashwagandha for Menopause

Shatavari and Ashwagandha are sometimes paired in practitioner-guided menopause care, but they are not interchangeable herbs. Shatavari is classically cooling, nourishing, unctuous, and rasayana in nature. Ashwagandha is more often selected when stress load, sleep difficulty, fatigue, and reduced strength are prominent. Recent trials have included both single-herb and combined-herb arms, supporting the practical Ayurvedic principle that the formula should match the woman’s constitution, symptom pattern, digestion, and medical history.

Practitioner-Guided Daily Framework

Morning: Shatavari extract in a dose appropriate to the product standardization, taken with food or a suitable anupana such as warm milk when tolerated.

Optional morning support: Ashwagandha may be added when stress, poor sleep, weakness, or nervous exhaustion are central features and when it is appropriate for the person’s constitution and medication profile.

Evening: Shatavari may be taken again if advised, or used in a small nourishing preparation before bed.

Weekly support: A gentle oil-based routine such as abhyanga may be considered when dryness, restlessness, poor sleep, or Vata-type symptoms are prominent.

The clinical trials used standardized extracts at specific doses, while traditional powder and kalpa-style preparations use different quantities. These forms should not be treated as directly equivalent. The Ayurvedic Pharmacopoeia of India lists the dose of Shatavari raw drug as 3–6 g, while modern trials have used standardized extracts ranging from 50 mg/day to 500 mg/day depending on the preparation.

Shatavari Kalpa: A Nourishing Bedtime Preparation

Shatavari Kalpa is listed among important formulations in the Ayurvedic Pharmacopoeia of India. Household kalpa-style preparations vary, and the version below is a simple food-like preparation inspired by the traditional idea of combining Shatavari with a nourishing carrier. It should not be presented as a substitute for a classical pharmacy-made formulation.

Simple Shatavari Kalpa-Style Preparation

  • 100 g Shatavari root powder
  • 50 g ghee
  • 30 g jaggery powder or raw sugar
  • 1/2 teaspoon cardamom powder
  • A small pinch of nutmeg powder
  • A few saffron strands, optional

Method: Warm a heavy pan on low heat and gently dry-roast the Shatavari powder for a few minutes, taking care not to brown or burn it. Melt the ghee separately. Combine the powder, ghee, sweetener, and spices, then mix until uniform. Store in a clean glass jar and use a clean, dry spoon.

Use: Take 1/2 to 1 teaspoon mixed into warm milk at bedtime, or follow the dose advised by a qualified Ayurvedic practitioner.

The Ayurvedic reasoning behind this preparation is based on Shatavari’s madhura, shita, guru, and snigdha qualities. Warm milk and ghee provide a nourishing, unctuous medium, which is traditionally suited to dryness, depletion, and Vata-type discomfort when digestion is strong enough to tolerate it.

Side Effects and Safety Considerations

Shatavari was generally well tolerated in the recent clinical trials, but it is still a biologically active herb and should be used with appropriate caution. Women with complex symptoms, active medical diagnoses, cancer history, hormone-sensitive conditions, pregnancy, breastfeeding, kidney or liver disease, or regular medication use should consult a qualified healthcare provider and an experienced Ayurvedic practitioner before using it.

  • Estrogen-sensitive conditions: Shatavari has phytoestrogenic activity. Women with a history of estrogen-receptor-positive breast cancer, endometriosis, fibroids, unexplained bleeding, or other hormone-sensitive conditions should seek medical guidance before use.
  • Hormone therapy: Combining Shatavari with HRT or other hormone-active therapies should not be done without clinical supervision.
  • Allergy: Anyone with a known allergy to Shatavari or related asparagus-family products should avoid it.
  • Digestive sensitivity: Mild bloating, nausea, loose stools, or gastrointestinal discomfort may occur in some people. Starting low and stopping if symptoms worsen is prudent.
  • Pregnancy and breastfeeding: Use only under professional supervision, especially because product quality, dose, and individual suitability vary.

Herb-drug interaction data for Shatavari remain limited. This makes professional guidance especially important for women taking HRT, thyroid medication, psychiatric medication, anticoagulants, fertility medicines, cancer therapies, diuretics, diabetes medication, or multiple long-term prescriptions.

A Practitioner-Guided Herbal Framework for Menopause

Shatavari can serve as the anchor herb when the presentation includes heat, dryness, poor sleep, irritability, vaginal dryness, night sweats, or depleted strength. A qualified practitioner may use it alone or combine it with other herbs depending on constitution, digestion, sleep quality, bowel pattern, emotional state, bleeding history, bone health, cardiovascular risk, and medication profile.

  1. Shatavari: Traditionally used as a nourishing rasayana and women’s-health herb; recent trials used standardized extracts in peri- and post-menopausal women.
  2. Ashwagandha: Considered when stress, fatigue, sleep difficulty, or low strength is central; recent trials have evaluated it alone and in combination with Shatavari.
  3. Dietary support: Warm, regular, nourishing meals may be preferred when dryness, irregular appetite, sleep disturbance, or Vata-type symptoms are prominent.
  4. Oil-based support: Gentle oil application may be used when dryness, restlessness, and sleep disturbance are part of the symptom picture.

This framework should be individualized. Menopause care is not only about suppressing hot flashes; it also involves sleep, mood, bone health, metabolic health, cardiovascular risk, vaginal comfort, digestion, and emotional steadiness.

Final Thoughts: What Women Going Through Menopause Should Know

Menopause is not a disease, but the symptoms can be real and disruptive. Conventional HRT remains an important option for many women, and Shatavari offers a plant-based Ayurvedic option with growing controlled-trial support for symptom relief, stress-related measures, quality of life, and endocrine modulation in selected peri- and post-menopausal populations.

For women considering Shatavari, a practical approach is to choose a quality-tested product, begin with a conservative dose, use it consistently for at least 8 weeks unless side effects occur, and track symptoms such as hot flashes, sleep, mood, vaginal dryness, and energy. Severe symptoms, postmenopausal bleeding, chest pain, fainting, sudden mood deterioration, or unexplained weight change should be evaluated medically rather than managed with herbs alone.

Frequently Asked Questions

The following answers summarize practical points for women considering Shatavari during perimenopause or menopause. Individual suitability depends on health history, symptom pattern, medications, digestion, and the form of Shatavari being used.

How long does it take for Shatavari to show results for menopause symptoms?

Recent trials measured outcomes over 8 weeks, 60 days, 120 days, and 24 weeks, depending on the formulation and study design. A reasonable minimum trial period for a suitable, well-tolerated product is about 8 weeks, with symptom tracking to assess changes in hot flashes, night sweats, sleep, mood, stress, and vaginal comfort.

Can Shatavari be taken alongside hormone replacement therapy?

Shatavari should not be combined with HRT or hormone-active treatment without medical supervision. Because Shatavari has phytoestrogenic activity and clinical interaction data are limited, women using HRT should speak with their gynecologist or healthcare provider before adding it.

What is the recommended dosage of Shatavari for menopause?

There is no single universal dose because clinical trials used different standardized extracts. Trials have used CL22209 at 50 mg/day and 100 mg/day, Shatavari root extract at 300 mg/day, 250 mg twice daily, and 250–500 mg/day in other extract forms. The Ayurvedic Pharmacopoeia of India lists 3–6 g as the dose of the raw drug. Product standardization, extract strength, digestion, constitution, and medical history should guide the final dose.

Is Shatavari safe for long-term use?

The recent menopause trials were generally short to medium duration, ranging from 8 weeks to 24 weeks, and reported good tolerability in the studied populations. Long-term use should be supervised, especially in women with hormone-sensitive conditions, cancer history, unexplained bleeding, pregnancy, breastfeeding, kidney or liver disease, or regular medication use.

Disclaimer: This article is for educational purposes and does not replace medical advice, diagnosis, or treatment. Menopause symptoms can overlap with thyroid disease, cardiovascular concerns, anemia, mood disorders, medication effects, and other medical conditions. Please consult a qualified healthcare provider and, when using Ayurvedic herbs, a qualified Ayurvedic practitioner for an individualized plan.

References

  1. Miracledrinksclinic (miracledrinksclinic.com)
  2. Ffhdj (ffhdj.com)
  3. Efficacy and Safety of Shatavari Root Extract for the Management of Menopausal Symptoms: A Double-Blind, Multicenter, Randomized Controlled Trial (2024), PubMed
  4. Cureus (cureus.com)
  5. Tandfonline (tandfonline.com)
  6. Frontiersin (frontiersin.org)
  7. E-jmm (e-jmm.org)
  8. Shatavari Supplementation in Postmenopausal Women Improves Handgrip Strength and Increases Vastus lateralis Myosin Regulatory Light Chain Phosphorylation but Does Not Alter Markers of Bone Turnover (2021), PubMed Central
  9. Drugs (drugs.com)